BioMarin's ROCTAVIAN Wins Food and Drug Administration Approval As First Gene Therapy for Severe Hemophilia A-MedSci.cn

BioMarin's ROCTAVIAN Wins Food and Drug Administration Approval As First Gene Therapy for Severe Hemophilia A

Philippidis, A

Philippidis, A (通讯作者)，Mary Ann Liebert Inc, New Rochelle, NY 10801 USA.

HUMAN GENE THERAPY, 2023; 34 (15-16): 665

科室
- - 订阅+
  - 更多科室
工具
服务